Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Expands IP Portfolio via Academic Collaborations

NEW YORK (GenomeWeb News) - Oxford Nanopore Technologies said today that it has signed a number of agreements with academic research institutions in order to expand its intellectual property portfolio around nanopore sensing technology.

The company said it has entered into collaborations with the University of Illinois at Urbana-Champaign, Brown University, Stanford University, Boston University, the University of Cambridge, and the University of Southampton.

While it did not disclose specific technologies covered by any of the licensing agreements, it said that its expanded IP portfolio now includes technology related to a broad range of applications, including DNA base identification using a biological nanopore; characterization of individual polymer molecules based on monomer-interface interactions; addition of adapters to nanopores for sensing; genetically modified nanopores for sensing; the use of molecular motors in combination with nanopores; the use of solid state devices to control movement of polymers; sequencing by means of detection of products of enzymatic action on DNA/RNA using a nanopore; and more.

Oxford Nanopore said that its IP portfolio includes more than 300 issued patents and patent applications in more than 80 patent families.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.